Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$32.09 - $37.51 $46,658 - $54,539
-1,454 Reduced 34.37%
2,776 $92,000
Q2 2023

Aug 09, 2023

BUY
$36.12 - $41.79 $8,163 - $9,444
226 Added 5.64%
4,230 $155,000
Q1 2023

May 10, 2023

SELL
$39.39 - $51.28 $52,861 - $68,817
-1,342 Reduced 25.1%
4,004 $163,000
Q4 2022

Feb 13, 2023

BUY
$41.75 - $54.5 $133,349 - $174,073
3,194 Added 148.42%
5,346 $274,000
Q3 2022

Nov 10, 2022

SELL
$43.76 - $53.42 $44,416 - $54,221
-1,015 Reduced 32.05%
2,152 $94,000
Q2 2022

Aug 08, 2022

SELL
$46.53 - $55.17 $35,921 - $42,591
-772 Reduced 19.6%
3,167 $166,000
Q1 2022

May 11, 2022

SELL
$45.75 - $56.69 $130,982 - $162,303
-2,863 Reduced 42.09%
3,939 $204,000
Q4 2021

Feb 11, 2022

BUY
$41.32 - $61.25 $39,667 - $58,800
960 Added 16.43%
6,802 $402,000
Q3 2021

Nov 12, 2021

SELL
$39.25 - $50.42 $194,248 - $249,528
-4,949 Reduced 45.86%
5,842 $251,000
Q2 2021

Aug 10, 2021

BUY
$35.91 - $40.68 $81,587 - $92,424
2,272 Added 26.67%
10,791 $423,000
Q1 2021

May 14, 2021

SELL
$33.49 - $37.77 $426,763 - $481,303
-12,743 Reduced 59.93%
8,519 $309,000
Q4 2020

Feb 12, 2021

BUY
$33.47 - $42.56 $213,639 - $271,660
6,383 Added 42.9%
21,262 $783,000
Q3 2020

Oct 30, 2020

SELL
$31.75 - $37.25 $195,802 - $229,720
-6,167 Reduced 29.3%
14,879 $546,000
Q2 2020

Aug 13, 2020

BUY
$30.12 - $36.54 $633,905 - $769,020
21,046 New
21,046 $688,000
Q4 2019

Feb 14, 2020

SELL
$32.92 - $37.36 $1.17 Million - $1.33 Million
-35,574 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$32.49 - $42.13 $1.16 Million - $1.5 Million
35,574 New
35,574 $1.28 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $147B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Rock Creek Group, LP Portfolio

Follow Rock Creek Group, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Creek Group, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Creek Group, LP with notifications on news.